ScholarIQanswers from OpenAlex & ORCID
Martee L. Hensley
ResearcherPublications, citations & collaboration network
Martee L. Hensley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Martee L. Hensley have?
ScholarIQindexed works
Martee L. Hensley has 382 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Martee L. Hensley have?
ScholarIQcitation count
Martee L. Hensley has 19,656 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Martee L. Hensley?
ScholarIQh-index
Martee L. Hensley has an h-index of 68 in OpenAlex.
What is the i10-index of Martee L. Hensley?
ScholarIQi10-index
Martee L. Hensley has an i10-index of 175 in OpenAlex.
What is the ORCID of Martee L. Hensley?
ScholarIQorcid
The ORCID for Martee L. Hensley is on the source record.
What is the OpenAlex record for Martee L. Hensley?
ScholarIQopenalex
The OpenAlex for Martee L. Hensley is on the source record.
What are the most-cited papers on Martee L. Hensley?
ScholarIQmost cited works
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur P. Staddon, Mohammed Milhem, A. Elias, Kristen N. Ganjoo, Hussein A. Tawbi, Brian Andrew Van Tine, Alexander I. Spira, Andrew Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, Trilok Parekh, Robert G. Maki, Shreyaskumar Patel
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel, Dennis A. Priebat, Scott H. Okuno, Brian L. Samuels, Michael Fanucchi, David C. Harmon, Scott M. Schuetze, Denise K. Reinke, Peter F. Thall, Robert S. Benjamin, Laurence H. Baker, Martee L. Hensley
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman, Gennifer Geller, Meghan Lovegren, Carol Aghajanian, Paul Sabbatini, William P. Tong, Richard R. Barakat, David R. Spriggs
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Michael Saulle, Scott M. Schuetze, Samir D. Undevia, Michael B. Livingston, Matthew M. Cooney, Martee L. Hensley, Monica Mita, Chris H. Takimoto, Andrew S. Kraft, Anthony Elias, Bruce Brockstein, Nathalie E. Blachère, Mark Edgar, Lawrence H. Schwartz, Li-Xuan Qin, Cristina R. Antonescu, Gary K. Schwartz
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley, John A. Blessing, Koen DeGeest, Ovadia Abulafia, Peter G. Rose, Howard D. Homesley